Capivasertib companion diagnostic - Foundation Medicine

Alternative Names: AZD-5363 companion diagnostic - Foundation Medicine; Truqap™ companion diagnostic - Foundation Medicine

Latest Information Update: 05 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Mar 2024 Registered for HER2-negative-breast-cancer (Diagnosis) in Japan (unspecified route)
22 Nov 2023 Foundation Medicine and AstraZeneca enters into an agreement to develop companion diagnostic assays to facilitate personalized medicine in cancer by identifying patients most likely to benefit from medicines within AstraZeneca's oncology pipeline
16 Nov 2023 Registered for HER2-negative-breast-cancer (Diagnosis) in USA (unspecified route) - First global approval

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com